

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



邁博藥業
Mabpharm Limited
迈博药业有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2181)

**(1) RESIGNATION OF EXECUTIVE DIRECTOR AND
NON-EXECUTIVE DIRECTOR**
**(2) APPOINTMENT OF EXECUTIVE DIRECTOR AND
NON-EXECUTIVE DIRECTOR**

The Board hereby announces that, with effect from November 28, 2023:

- (i) Mr. Guo Jianjun will resign as a non-executive Director;
- (ii) Dr. Li Jing will resign as an executive Director;
- (iii) Dr. Hou Sheng will be appointed as an executive Director; and
- (iv) Dr. Qian Weizhu will be appointed as a non-executive Director.

The board (the “**Board**”) of directors (the “**Directors**”, and each a “**Director**”) of Mabpharm Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces the following changes in composition of the Board.

I. RESIGNATION OF DIRECTORS

With effect from November 28, 2023, Mr. Guo Jianjun (“**Mr. Guo**”) will resign as a non-executive Director due to age concern and Dr. Li Jing (“**Dr. Li**”) will resign as an executive Director in order to devote more time to her other personal commitments.

Mr. Guo and Dr. Li have confirmed that they have no disagreement with the Board and they are not aware of any matter in relation to their resignation as Directors that should be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

II. APPOINTMENT OF DIRECTORS

With effect from November 28, 2023, Dr. Hou Sheng (“**Dr. Hou**”) and Dr. Qian Weizhu (“**Dr. Qian**”) will be appointed as an executive Director and non-executive Director respectively.

The biographical details of Dr. Hou and Dr. Qian are set out below.

Dr. Hou Sheng (侯盛), aged 46, has over 20 years of experience in oncology and biology fields. Dr. Hou served as an assistant researcher and associate researcher and was employed at translational medical research department on tumor cell biology of Second Military Medical University (第二軍醫大學) (currently known as People’s Liberation Army Navy Medical University (中國人民解放軍海軍軍醫大學)) from May 2008 to March 2016. From May 2008 to August 2012, Dr. Hou served as an assistant researcher and associate researcher at National Engineering Research Center for Antibody Medicine* (抗體藥物國家工程研究中心). From September 2012 to February 2021, Dr. Hou served as a deputy director and associate researcher at State Key Laboratory of Antibody Drugs and Targeted Therapy (抗體藥物與靶向治療國家重點實驗室). From April 2021 to July 2023, Dr. Hou was the chairman of the board of directors and general manager of Wuhan Guojian Baiao Pharmaceutical Co., Ltd* (武漢國健百奧藥業有限公司). Dr. Hou is the spouse of Dr. Qian.

Dr. Hou obtained his bachelor’s degree in medicine from Second Military Medical University (第二軍醫大學) (currently known as People’s Liberation Army Navy Medical University (中國人民解放軍海軍軍醫大學)) in June 2000, and was awarded his master’s and doctorate degrees in oncology from the aforementioned university in June 2005.

Dr. Hou received second prize in State Technological Invention Award (國家技術發明二等獎) in 2007, first prize in Shanghai Science and Technology Award (上海市科學技術獎一等獎) two times in 2006 and 2011 respectively, and second prize in Shanghai Technology Invention Award (上海市技術發明獎二等獎).

The Company has entered into a service contract with Dr. Hou for his appointment as an executive Director for a term of three years commencing from November 28, 2023, subject to retirement by rotation and re-election at annual general meetings of the Company in accordance with the articles of association of the Company (the “**Articles of Association**”) and the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”). In accordance with Dr. Hou’s service contract, Dr. Hou is entitled to a director’s fee of RMB850,000.00 per annum and discretionary bonus as determined by the Board. His emoluments were recommended by the remuneration committee of the Company and approved by the Board with reference to his duties and responsibilities as well as his qualifications, experience and the prevailing market conditions.

Dr. Qian Weizhu (錢衛珠), aged 48, currently serves as the vice president of Shanghai Biomabs Pharmaceuticals Co., Ltd.* (上海百邁博製藥有限公司) (“**Biomabs**”) and the consultant of the Company. Dr. Qian has more than 25 years of experience in oncology and biology fields. Dr. Qian was employed at the Cancer Institute of Second Military Medical University (第二軍醫大學) (currently known as People’s Liberation Army Navy Medical University (中國人民解放軍海軍軍醫大學)) from 1994 to 2013, primarily responsible for biotechnology research and development. Dr. Qian consecutively served as deputy general manager and general manager of Shanghai Zhangjiang Biotechnology Co., Ltd.* (上海張江生物技術有限公司) from January 2014 to July 2017. Dr. Qian worked as a director and general manager in Biomabs from October 2015 to August 2018 and from December 2020 to October 2023. Dr. Qian also served as general manager in Shanghai Sinomab Biotechnology Co., Ltd.* (上海邁泰君奧生物技術有限公司) from February 2016 to August 2018. Dr. Qian was a legal representative of Shanghai Guojian Biotechnology Research Institute (上海國健生物技術研究院) from February 2015 to September 2018. Dr. Qian joined our Group in February 2015, and served consecutively as a director and chairman of the board of directors in Taizhou Mabtech Pharmaceutical Limited* (泰州邁博太科藥業有限公司) (“**Taizhou Pharmaceutical**”) from February 2015 to October 2020, during which she had been deputy general manager and general manager of Taizhou Pharmaceutical consecutively from February 2015 to August 2018. Dr. Qian served as the executive director and chief executive officer of the Company from July 2018 to October 2020. Dr. Qian is the spouse of Dr. Hou.

Dr. Qian obtained a master’s degree in biochemistry and molecular biology in June 2003 from Second Military Medical University (第二軍醫大學) (currently known as People’s Liberation Army Navy Medical University (中國人民解放軍海軍軍醫大學)) and was awarded a doctorate degree in oncology in June 2011 from the aforementioned university.

The Company has entered into a letter of appointment with Dr. Qian for her appointment as a non-executive Director for a term of three years commencing from November 28, 2023, subject to retirement by rotation and re-election at annual general meetings of the Company in accordance with the Articles of Association and the Listing Rules. In accordance with Dr. Qian’s letter of appointment, Dr. Qian will not receive any director’s fee or other remuneration for holding her office as a non-executive Director except for any discretionary bonus as determined by the Board.

On August 18, 2018, Dr. Qian was granted 29,642,137 share options, representing the rights to subscribe for 29,642,137 shares of the Company. As at the date of this announcement, Dr. Qian is entitled to exercise 5,928,427 share options. As Dr. Hou is the husband of Dr. Qian, he is deemed to be interested in the 29,642,137 share options held by Dr. Qian under the Securities and Futures Ordinance, Chapter 571 of the laws of Hong Kong (the “SFO”).

Save as disclosed above, as at the date of this announcement, Dr. Hou and Dr. Qian (i) have not held any directorship in any listed public companies in the last three years, the securities of which are listed on any securities market in Hong Kong or overseas; (ii) do not have any other major appointment or professional qualification; (iii) do not have any interest or is not deemed to be interested in any shares or underlying shares of the Company within the meaning of Part XV of the SFO; and (iv) do not have any relationship with any other directors, senior management or substantial or controlling shareholders of the Company or its subsidiaries.

Save as disclosed above, there is no other matter in relation to the appointment of Dr. Hou and Dr. Qian that needs to be brought to the attention of the Shareholders or the Stock Exchange, nor any information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules.

IV. ACKNOWLEDGEMENT

The Board would like to express its sincere gratitude to Mr. Guo and Dr. Li for their contribution to the Group during their term of service as Director. The Board would also like to extend its warmest welcome to Dr. Hou and Dr. Qian on their new appointments.

By Order of the Board
Mabpharm Limited
Jiao Shuge
Chairman

Hong Kong, November 28, 2023

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Wang Hao, Mr. Tao Jing, Mr. Li Yunfeng, and Dr. Hou Sheng as executive Directors; Mr. Jiao Shuge and Dr. Qian Weizhu as non-executive Directors; and Mr. Guo Liangzhong, Dr. Zhang Yanyun and Mr. Leung, Louis Ho Ming as independent non-executive Directors.

* *For identification purpose only*